SG11201703767XA - Anti-interleukin-33 antibodies and uses thereof - Google Patents

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Genetics & Genomics (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biomedical Technology (AREA)
Pulmonology (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Oncology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Ophthalmology & Optometry (AREA)
General Engineering & Computer Science (AREA)
Zoology (AREA)
Biotechnology (AREA)
Wood Science & Technology (AREA)
Microbiology (AREA)
Endocrinology (AREA)
Cardiology (AREA)
Rheumatology (AREA)
Tropical Medicine & Parasitology (AREA)
Pain & Pain Management (AREA)

SG11201703767XA2014-11-102015-11-10Anti-interleukin-33 antibodies and uses thereofSG11201703767XA (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201462077876P	2014-11-10	2014-11-10
US201562165732P	2015-05-22	2015-05-22
PCT/US2015/060008WO2016077381A1 (en)	2014-11-10	2015-11-10	Anti-interleukin-33 antibodies and uses thereof

Publications (1)

Publication Number	Publication Date
SG11201703767XAtrue SG11201703767XA (en)	2017-06-29

Family

ID=54608970

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11201703767XASG11201703767XA (en)	2014-11-10	2015-11-10	Anti-interleukin-33 antibodies and uses thereof

Country Status (18)

Country	Link
US (3)	US10093730B2 (en)
EP (2)	EP3783023A1 (en)
JP (1)	JP6929771B2 (en)
KR (1)	KR20170080604A (en)
CN (1)	CN107172879B (en)
AU (1)	AU2015346460A1 (en)
BR (1)	BR112017009728A2 (en)
CA (1)	CA2960297A1 (en)
CO (1)	CO2017005650A2 (en)
CR (1)	CR20170240A (en)
EA (1)	EA201791029A1 (en)
IL (1)	IL251248A0 (en)
MX (1)	MX2017006094A (en)
PE (1)	PE20170910A1 (en)
PH (1)	PH12017500861A1 (en)
SG (1)	SG11201703767XA (en)
TW (1)	TWI705976B (en)
WO (1)	WO2016077381A1 (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2013188316A1 (en)*	2012-06-11	2013-12-19	Avalanche Biotechnologies, Inc.	Optical regulation of gene expression in the retina
JP2017503506A (en)	2014-01-10	2017-02-02	アナプティスバイオインコーポレイティッド	Antibody to interleukin-33 (IL-33)
US20160168640A1 (en)	2014-11-10	2016-06-16	Genentech, Inc.	Therapeutic and diagnostic methods for il-33-mediated disorders
KR20170080604A (en)	2014-11-10	2017-07-10	제넨테크, 인크.	Anti-interleukin-33 antibodies and uses thereof
CN108137681B (en)	2015-09-23	2024-06-18	豪夫迈·罗氏有限公司	Optimized variants of anti-VEGF antibodies
JP2019516362A (en)	2016-04-27	2019-06-20	ファイザー・インク	Anti-IL-33 antibodies, compositions, methods and uses thereof
JP6871948B2 (en)	2016-04-27	2021-05-19	アッヴィ・インコーポレイテッド	Treatment of Diseases with Harmful IL-13 Activity Using Anti-IL-13 Antibodies
WO2018045210A1 (en)*	2016-09-02	2018-03-08	Therapeutics Lp 180	Method of treating localized fibrotic disorders using an il-33/tnf bispecific antibody
WO2018045213A1 (en)*	2016-09-02	2018-03-08	180 Therapeutics Lp	Method of treating systemic fibrotic disorders using an il-33/tnf bispecific antibody
JOP20190093A1 (en)*	2016-10-28	2019-04-25	Lilly Co Eli	Anti-il-33 antibodies and uses thereof
TWI857389B (en)	2016-12-01	2024-10-01	美商再生元醫藥公司	Methods of treating inflammatory conditions
CR20190387A (en)	2017-02-10	2019-09-25	Genentech Inc	ANTIBODIES AGAINST TRYPTASE, COMPOSITIONS OF THESE AND USES OF THEM
WO2018190990A1 (en)	2017-04-13	2018-10-18	Regeneron Pharmaceuticals, Inc.	Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding il33 and il1rl1
CN110997725B (en)	2017-06-12	2024-08-09	蓝鳍生物医药公司	Anti-IL1RAP Antibodies and Antibody Drug Conjugates
AU2019218128A1 (en)	2018-02-09	2020-09-17	Genentech, Inc.	Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases
IL307286A (en)	2018-04-11	2023-11-01	Regeneron Pharma	Methods and compositions for quantifying il-33
CN108795934B (en)*	2018-05-23	2022-06-21	中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心)	SiRNA of schistosoma japonicum SjELAV-like 2 gene and application thereof
CN110551745A (en)*	2018-05-31	2019-12-10	康码（上海）生物科技有限公司	Multiple histidine sequence tag and application thereof in protein expression and purification
TW202021618A (en)	2018-08-17	2020-06-16	美商２３與我有限公司	Anti-il1rap antibodies and methods of use thereof
US12331320B2 (en)	2018-10-10	2025-06-17	The Research Foundation For The State University Of New York	Genome edited cancer cell vaccines
EP3877407A1 (en)	2018-11-05	2021-09-15	F. Hoffmann-La Roche AG	Methods of producing two chain proteins in prokaryotic host cells
TW202134261A (en)	2019-11-04	2021-09-16	英商梅迪繆思有限公司	Methods of using il-33 antagonists
US20220363748A1 (en)	2019-11-04	2022-11-17	Medimmune Limited	Anti il-33 therapeutic agent for treating renal disorders
TW202128748A (en)	2020-01-24	2021-08-01	日商西斯美股份有限公司	Method for improving affinity of antibody for antigen and use thereof
EP4118114A1 (en)	2020-03-13	2023-01-18	Genentech, Inc.	Anti-interleukin-33 antibodies and uses thereof
CN115315527A (en)	2020-03-13	2022-11-08	免疫医疗有限公司	Methods of treatment for subjects with at risk alleles in IL33
CA3176571A1 (en)	2020-04-06	2021-10-14	Medimmune Limited	Treating acute respiratory distress syndrome with il-33 axis binding antagonists
KR20230010239A (en)	2020-05-11	2023-01-18	메디뮨 리미티드	Formulations of Anti-IL-33 Antibodies
CN111378037B (en)*	2020-06-01	2020-09-01	南京诺艾新生物技术有限公司	anti-hIL-33 humanized monoclonal antibody and application thereof
CN116635064A (en)	2020-12-18	2023-08-22	世纪治疗股份有限公司	A chimeric antigen receptor system with adaptive receptor specificity
CN113603775B (en)*	2021-09-03	2022-05-20	江苏荃信生物医药股份有限公司	Anti-human interleukin-33 monoclonal antibody and application thereof
EP4430072A1 (en)	2021-11-10	2024-09-18	Genentech, Inc.	Anti-interleukin-33 antibodies and uses thereof
IL315262A (en)*	2022-03-03	2024-10-01	Pfizer	Multispecific antibodies binding to il-4, il-13 and/or tslp and uses thereof
WO2023178265A2 (en)*	2022-03-18	2023-09-21	Novascope Biochips Inc.	Antibody for porcine reproductive and respiratory syndrome virus and uses thereof
TW202402790A (en)	2022-03-25	2024-01-16	英商梅迪繆思有限公司	Methods for reducing respiratory infections
WO2023245187A2 (en)	2022-06-17	2023-12-21	Apogee Biologics, Inc.	Antibodies that bind interleukin 13 and methods of use
WO2024038185A1 (en)	2022-08-19	2024-02-22	Medimmune Limited	Method of selecting patients for treatment with an il-33 axis antagonist
JP7668943B2 (en)*	2023-08-30	2025-04-25	ファイザー・インク	Multispecific antibodies and uses thereof
WO2025114862A1 (en)*	2023-11-27	2025-06-05	Glaxosmithkline Intellectual Property Development Limited	Il-33 binding antibodies
WO2025120567A1 (en)	2023-12-07	2025-06-12	Medimmune Limited	Method of treatment of asthma

Family Cites Families (192)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4737456A (en)	1985-05-09	1988-04-12	Syntex (U.S.A.) Inc.	Reducing interference in ligand-receptor binding assays
US4676980A (en)	1985-09-23	1987-06-30	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Target specific cross-linked heteroantibodies
US6548640B1 (en)	1986-03-27	2003-04-15	Btg International Limited	Altered antibodies
IL85035A0 (en)	1987-01-08	1988-06-30	Int Genetic Eng	Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0307434B2 (en)	1987-03-18	1998-07-29	Scotgen Biopharmaceuticals, Inc.	Altered antibodies
US5770701A (en)	1987-10-30	1998-06-23	American Cyanamid Company	Process for preparing targeted forms of methyltrithio antitumor agents
US5606040A (en)	1987-10-30	1997-02-25	American Cyanamid Company	Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
WO1989006692A1 (en)	1988-01-12	1989-07-27	Genentech, Inc.	Method of treating tumor cells by inhibiting growth factor receptor function
FI903489A7 (en)	1988-11-11	1990-07-10	Medical Res Council	Ligands containing one moiety, receptors containing these ligands, methods for their preparation and uses of the ligands and receptors
DE3920358A1 (en)	1989-06-22	1991-01-17	Behringwerke Ag	BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
US5208020A (en)	1989-10-25	1993-05-04	Immunogen Inc.	Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en)	1989-10-25	2006-02-07	Ravi J. Chari	Cytotoxic agents comprising maytansinoids and their therapeutic use
US5959177A (en)	1989-10-27	1999-09-28	The Scripps Research Institute	Transgenic plants expressing assembled secretory antibodies
US6150584A (en)	1990-01-12	2000-11-21	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US6075181A (en)	1990-01-12	2000-06-13	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US5770429A (en)	1990-08-29	1998-06-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
ES2113940T3 (en)	1990-12-03	1998-05-16	Genentech Inc	ENRICHMENT METHOD FOR PROTEIN VARIANTS WITH ALTERED UNION PROPERTIES.
US5571894A (en)	1991-02-05	1996-11-05	Ciba-Geigy Corporation	Recombinant antibodies specific for a growth factor receptor
US6582959B2 (en)	1991-03-29	2003-06-24	Genentech, Inc.	Antibodies to vascular endothelial cell growth factor
US20030206899A1 (en)	1991-03-29	2003-11-06	Genentech, Inc.	Vascular endothelial cell growth factor antagonists
US6407213B1 (en)	1991-06-14	2002-06-18	Genentech, Inc.	Method for making humanized antibodies
WO1994004679A1 (en)	1991-06-14	1994-03-03	Genentech, Inc.	Method for making humanized antibodies
GB9114948D0 (en)	1991-07-11	1991-08-28	Pfizer Ltd	Process for preparing sertraline intermediates
EP0604580A1 (en)	1991-09-19	1994-07-06	Genentech, Inc.	EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
FI941572L (en)	1991-10-07	1994-05-27	Oncologix Inc	Combination and method of use of anti-erbB-2 monoclonal antibodies
WO1993008829A1 (en)	1991-11-04	1993-05-13	The Regents Of The University Of California	Compositions that mediate killing of hiv-infected cells
ATE207080T1 (en)	1991-11-25	2001-11-15	Enzon Inc	MULTIVALENT ANTIGEN-BINDING PROTEINS
EP0625200B1 (en)	1992-02-06	2005-05-11	Chiron Corporation	Biosynthetic binding protein for cancer marker
ATE215565T1 (en)	1992-10-28	2002-04-15	Genentech Inc	USE OF ANTI-VEGF ANTIBODIES TO TREAT CANCER
EP0752248B1 (en)	1992-11-13	2000-09-27	Idec Pharmaceuticals Corporation	Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5635483A (en)	1992-12-03	1997-06-03	Arizona Board Of Regents Acting On Behalf Of Arizona State University	Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en)	1993-01-26	1998-07-14	Arizona Board Of Regents	Elucidation and synthesis of selected pentapeptides
JPH08511420A (en)	1993-06-16	1996-12-03	セルテック・セラピューテイクス・リミテッド	Body
US5635388A (en)	1994-04-04	1997-06-03	Genentech, Inc.	Agonist antibodies against the flk2/flt3 receptor and uses thereof
US5773001A (en)	1994-06-03	1998-06-30	American Cyanamid Company	Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5789199A (en)	1994-11-03	1998-08-04	Genentech, Inc.	Process for bacterial production of polypeptides
US5731168A (en)	1995-03-01	1998-03-24	Genentech, Inc.	Method for making heteromultimeric polypeptides
US5840523A (en)	1995-03-01	1998-11-24	Genetech, Inc.	Methods and compositions for secretion of heterologous polypeptides
US6066322A (en)	1995-03-03	2000-05-23	Millennium Pharmaceuticals, Inc.	Methods for the treatment of immune disorders
IL117645A (en)	1995-03-30	2005-08-31	Genentech Inc	Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US5641870A (en)	1995-04-20	1997-06-24	Genentech, Inc.	Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en)	1995-04-14	1999-02-09	Genentech, Inc.	Altered polypeptides with increased half-life
US5712374A (en)	1995-06-07	1998-01-27	American Cyanamid Company	Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en)	1995-06-07	1998-02-03	American Cyanamid Company	Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US6267958B1 (en)	1995-07-27	2001-07-31	Genentech, Inc.	Protein formulation
GB9603256D0 (en)	1996-02-16	1996-04-17	Wellcome Found	Antibodies
US6884879B1 (en)	1997-04-07	2005-04-26	Genentech, Inc.	Anti-VEGF antibodies
US20020032315A1 (en)	1997-08-06	2002-03-14	Manuel Baca	Anti-vegf antibodies
SI0973804T1 (en)	1997-04-07	2007-06-30	Genentech Inc	Anti-vegf antibodies
ES2236634T3 (en)	1997-04-07	2005-07-16	Genentech, Inc.	ANTI-VEGF ANTIBODIES.
DK0979281T3 (en)	1997-05-02	2005-11-21	Genentech Inc	Process for the preparation of multispecific antibodies with heteromultimers and common components
US6171586B1 (en)	1997-06-13	2001-01-09	Genentech, Inc.	Antibody formulation
WO1998058964A1 (en)	1997-06-24	1998-12-30	Genentech, Inc.	Methods and compositions for galactosylated glycoproteins
US6040498A (en)	1998-08-11	2000-03-21	North Caroline State University	Genetically engineered duckweed
DE69840412D1 (en)	1997-10-31	2009-02-12	Genentech Inc	METHODS AND COMPOSITIONS CONTAINING GLYCOPROTEIN GLYCOR FORMS
US6610833B1 (en)	1997-11-24	2003-08-26	The Institute For Human Genetics And Biochemistry	Monoclonal human natural antibodies
DK1034298T3 (en)	1997-12-05	2012-01-30	Scripps Research Inst	Humanization of murine antibody
US6956107B2 (en)	1998-02-20	2005-10-18	Tanox, Inc.	Inhibitors of complement activation
ES2292236T3 (en)	1998-04-02	2008-03-01	Genentech, Inc.	VARIATIONS OF ANTIBODIES AND THEIR FRAGMENTS.
US6194551B1 (en)	1998-04-02	2001-02-27	Genentech, Inc.	Polypeptide variants
WO1999054342A1 (en)	1998-04-20	1999-10-28	Pablo Umana	Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
US6737056B1 (en)	1999-01-15	2004-05-18	Genentech, Inc.	Polypeptide variants with altered effector function
HUP0104865A3 (en)	1999-01-15	2004-07-28	Genentech Inc	Polypeptide variants with altered effector function
EP3031917A1 (en)	1999-04-09	2016-06-15	Kyowa Hakko Kirin Co., Ltd.	Method for controlling the activity of immunologically functional molecule
US6703020B1 (en)	1999-04-28	2004-03-09	Board Of Regents, The University Of Texas System	Antibody conjugate methods for selectively inhibiting VEGF
US6323334B1 (en)	1999-09-24	2001-11-27	Millennium Pharmaceuticals, Inc.	Nucleic acid molecules encoding a 103 gene product and uses therefor
US7125978B1 (en)	1999-10-04	2006-10-24	Medicago Inc.	Promoter for regulating expression of foreign genes
KR100797667B1 (en)	1999-10-04	2008-01-23	메디카고 인코포레이티드	How to regulate transcription of foreign genes
EP1229125A4 (en)	1999-10-19	2005-06-01	Kyowa Hakko Kogyo Kk	PROCESS FOR PRODUCING A POLYPEPTIDE
JP2003516755A (en)	1999-12-15	2003-05-20	ジェネンテック・インコーポレーテッド	Shotgun scanning, a combined method for mapping functional protein epitopes
NZ518764A (en)	1999-12-29	2004-02-27	Immunogen Inc	Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
WO2001070817A1 (en)	2000-03-21	2001-09-27	Medical & Biological Laboratories Co., Ltd.	Monoclonal antibody and method and kit for the immunoassay of soluble human st2 with the use of the same
ES2329010T3 (en)	2000-03-23	2009-11-20	Genentech, Inc.	ANTI-C2 / C2A INHIBITORS OF COMPLEMENT ACTIVATION.
KR20020093029A (en)	2000-04-11	2002-12-12	제넨테크, 인크.	Multivalent Antibodies And Uses Therefor
US6946292B2 (en)	2000-10-06	2005-09-20	Kyowa Hakko Kogyo Co., Ltd.	Cells producing antibody compositions with increased antibody dependent cytotoxic activity
EA013563B1 (en)	2000-10-06	2010-06-30	Киова Хакко Кирин Ко., Лтд.	A transgenic non-human animal, producing antibodies with modified sugar chains, a process for producing antibodies composition and a medicament comprising the antibodies
US7064191B2 (en)	2000-10-06	2006-06-20	Kyowa Hakko Kogyo Co., Ltd.	Process for purifying antibody
US6596541B2 (en)	2000-10-31	2003-07-22	Regeneron Pharmaceuticals, Inc.	Methods of modifying eukaryotic cells
ES2405944T3 (en)	2000-11-30	2013-06-04	Medarex, Inc.	Nucleic acids encoding reorganized human immunoglobulin sequences from transgenic transchromosomal micezadas
NZ592087A (en)	2001-08-03	2012-11-30	Roche Glycart Ag	Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
PL213948B1 (en)	2001-10-25	2013-05-31	Genentech Inc	Glycoprotein compositions
US20040093621A1 (en)	2001-12-25	2004-05-13	Kyowa Hakko Kogyo Co., Ltd	Antibody composition which specifically binds to CD20
PL373256A1 (en)	2002-04-09	2005-08-22	Kyowa Hakko Kogyo Co, Ltd.	Cells with modified genome
EP1502603A4 (en)	2002-04-09	2006-12-13	Kyowa Hakko Kogyo Kk	MEDICAMENT CONTAINING ANTIBODY COMPOSITION APPROPRIATE TO PATIENT SUFFERING FROM POLYMORPHISM FC gammma RIIIA
ES2362419T3 (en)	2002-04-09	2011-07-05	Kyowa Hakko Kirin Co., Ltd.	CELLS WITH DEPRESSION OR DELETION OF THE ACTIVITY OF THE PROTEIN THAT PARTICIPATES IN THE TRANSPORT OF GDP-FUCOSA.
JPWO2003085119A1 (en)	2002-04-09	2005-08-11	協和醗酵工業株式会社	Method for enhancing binding activity of antibody composition to Fcγ receptor IIIa
AU2003236015A1 (en)	2002-04-09	2003-10-20	Kyowa Hakko Kirin Co., Ltd.	Process for producing antibody composition
CA2481920A1 (en)	2002-04-09	2003-10-16	Kyowa Hakko Kogyo Co., Ltd.	Antibody composition-containing medicament
CA2488441C (en)	2002-06-03	2015-01-27	Genentech, Inc.	Synthetic antibody phage libraries
US7361740B2 (en)	2002-10-15	2008-04-22	Pdl Biopharma, Inc.	Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP2301966A1 (en)	2002-12-16	2011-03-30	Genentech, Inc.	Immunoglobulin variants and uses thereof
WO2004056868A2 (en)	2002-12-19	2004-07-08	Endocube Sas	Nf-hev compositions and methods of use
EP1585767A2 (en)	2003-01-16	2005-10-19	Genentech, Inc.	Synthetic antibody phage libraries
US7871607B2 (en)	2003-03-05	2011-01-18	Halozyme, Inc.	Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en)	2003-03-05	2006-05-18	Halozyme, Inc.	Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
RS20150135A1 (en)	2003-05-30	2015-08-31	Genentech Inc.	Treatment with anti-vegf antibodies
WO2005044853A2 (en)	2003-11-01	2005-05-19	Genentech, Inc.	Anti-vegf antibodies
US20050106667A1 (en)	2003-08-01	2005-05-19	Genentech, Inc	Binding polypeptides with restricted diversity sequences
US20080241884A1 (en)	2003-10-08	2008-10-02	Kenya Shitara	Fused Protein Composition
US20070134759A1 (en)	2003-10-09	2007-06-14	Harue Nishiya	Process for producing antibody composition by using rna inhibiting the function of alpha1,6-fucosyltransferase
DE602004026470D1 (en)	2003-11-05	2010-05-20	Roche Glycart Ag	FC RECEPTOR AND EFFECTOR FUNCTION
EP3858387A1 (en)	2003-11-06	2021-08-04	Seagen Inc.	Monomethylvaline compounds capable of conjugation to ligands
JPWO2005053742A1 (en)	2003-12-04	2007-06-28	協和醗酵工業株式会社	Medicament containing antibody composition
JP4851944B2 (en)	2003-12-23	2012-01-11	ジェネンテック，インコーポレイテッド	Novel anti-IL13 antibody and use thereof
NZ549040A (en)	2004-02-17	2009-07-31	Schering Corp	Use for interleukin-33 (IL33) and the IL-33 receptor complex
CN1961003B (en)	2004-03-31	2013-03-27	健泰科生物技术公司	Humanized anti-TGF-beta antibodies
US7785903B2 (en)	2004-04-09	2010-08-31	Genentech, Inc.	Variable domain library and uses
PL1737891T3 (en)	2004-04-13	2013-08-30	Hoffmann La Roche	Anti-p-selectin antibodies
US20060009360A1 (en)	2004-06-25	2006-01-12	Robert Pifer	New adjuvant composition
TWI309240B (en)	2004-09-17	2009-05-01	Hoffmann La Roche	Anti-ox40l antibodies
WO2006034488A2 (en)	2004-09-23	2006-03-30	Genentech, Inc.	Cysteine engineered antibodies and conjugates
JO3000B1 (en)	2004-10-20	2016-09-05	Genentech Inc	Antibody Formulations.
CN107929731A (en)	2005-11-04	2018-04-20	健泰科生物技术公司	Utilize complement pathway inhibitors to treat ocular diseases
ES2577292T3 (en)	2005-11-07	2016-07-14	Genentech, Inc.	Binding polypeptides with diversified VH / VL hypervariable sequences and consensus
US20070237764A1 (en)	2005-12-02	2007-10-11	Genentech, Inc.	Binding polypeptides with restricted diversity sequences
US8187569B2 (en)	2006-02-14	2012-05-29	Exxonmobil Chemical Patents Inc.	Process for manufacturing molecular sieve of MFS framework type and its use
EP2386860B1 (en)	2006-04-24	2014-11-05	Critical Care Diagnostics, Inc.	Predicting mortality and detecting severe disease
WO2007143295A2 (en)	2006-04-27	2007-12-13	Critical Care Diagnostics, Inc.	Interleukin-33 (il-33) for the diagnosis and prognosis of cardiovascular disease
EP2995951B1 (en)	2006-05-02	2019-02-13	Critical Care Diagnostics, Inc.	Method for selecting treatment based on differential diagnosis between pulmonary and cardiovascular disease
US8147817B2 (en)	2006-05-04	2012-04-03	The Brigham And Women's Hospital, Inc.	IL-33 in the treatment and diagnosis of diseases and disorders
JP2009536527A (en)	2006-05-09	2009-10-15	ジェネンテック・インコーポレーテッド	Binding polypeptide with optimized scaffold
WO2007140205A2 (en)	2006-05-24	2007-12-06	Biogen Idec Ma Inc.	Methods of treating fibrosis
EP2035456A1 (en)	2006-06-22	2009-03-18	Novo Nordisk A/S	Production of bispecific antibodies
US7560530B1 (en)	2006-07-20	2009-07-14	Schering Corporation	IL-33 receptor
WO2008027236A2 (en)	2006-08-30	2008-03-06	Genentech, Inc.	Multispecific antibodies
SE532250C2 (en)	2006-11-28	2009-11-24	Theravac Pharmaceuticals Ab	New formulations of IL-33 for the treatment of inflammatory conditions with a strong TH2 component by vaccination
US20080226635A1 (en)	2006-12-22	2008-09-18	Hans Koll	Antibodies against insulin-like growth factor I receptor and uses thereof
US8119771B2 (en)	2007-04-26	2012-02-21	The Provost, Fellow and Scholars of the College of the Holy and Undivided Trinity of Queen Elizabeth, Near Dublin	Products for altering IL-33 activity and methods thereof
US20100260770A1 (en)	2007-05-18	2010-10-14	Medimmune, Llc	Il-33 in inflammatory disease
CN100592373C (en)	2007-05-25	2010-02-24	群康科技(深圳)有限公司	Liquid crystal display panel driving device and driving method thereof
EP2211905A1 (en)	2007-10-26	2010-08-04	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.	Inhibitors of caspase i-dependent cytokines in the treatment of neurodegenerative disorders
PL2235064T3 (en)	2008-01-07	2016-06-30	Amgen Inc	Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
US20110045501A1 (en)	2008-01-08	2011-02-24	Irene Bosch	St2-based dengue fever diagnostic
CN102046660A (en)	2008-03-26	2011-05-04	塞勒兰特治疗公司	Immunoglobulin and/or toll-like receptor proteins associated with myelogenous haematological proliferative disorders and uses thereof
HRP20170615T1 (en)	2008-06-25	2017-07-28	Esbatech, An Alcon Biomedical Research Unit Llc	Stable and soluble antibodies inhibiting vegf
US8383778B2 (en)	2009-01-29	2013-02-26	Abbvie Inc.	IL-1 binding proteins
US20110165063A1 (en)	2009-01-29	2011-07-07	Abbott Laboratories	Il-1 binding proteins
MX2011009362A (en)	2009-03-05	2011-09-26	Abbott Lab	Il-17 binding proteins.
JP5428422B2 (en)	2009-03-17	2014-02-26	ヤマハ株式会社	Electronic musical instruments
EP2475388B1 (en)	2009-09-10	2017-11-08	Merck Sharp & Dohme Corp.	Use of il-33 antagonists to treat fibrotic disease
UY32949A (en)	2009-10-15	2011-02-28	Abbott Lab	IL-1 UNION PROTEINS
TWI426920B (en)	2010-03-26	2014-02-21	Hoffmann La Roche	Bispecific, bivalent anti-VEGF/anti-ANG-2 antibody
MX346731B (en)	2010-04-23	2017-03-30	Genentech Inc *	Production of heteromultimeric proteins.
PE20130205A1 (en)	2010-05-14	2013-03-24	Abbvie Inc	IL-1 BINDING PROTEINS
WO2012055891A1 (en)	2010-10-29	2012-05-03	F. Hoffmann-La Roche Ag	Murine model of inflammation with il33 n-terminal domain deletion
BR122020012255B1 (en)	2010-12-16	2022-08-09	Genentech, Inc	USE OF AN ANTI-IL-13 ANTIBODY, USES OF A TH2 PATHWAY INHIBITOR AND ANTI-PERIOSTIN ANTIBODIES
US20120275996A1 (en)	2010-12-21	2012-11-01	Abbott Laboratories	IL-1 Binding Proteins
WO2012103240A2 (en)	2011-01-25	2012-08-02	Eleven Biotherapeutics, Inc.	Receptor binding agents
RU2597288C2 (en)	2011-02-23	2016-09-10	Ф. Хоффманн-Ля Рош Аг	Antibodies against human il33r and use thereof
FR2972006B1 (en)	2011-02-24	2016-03-25	Centre Nat Rech Scient	NOVEL IL-33 SUPERACTIVE FRAGMENTS AND USES THEREOF
US20150306139A1 (en)	2011-04-21	2015-10-29	Jeffrey Ravetch	Anti-inflammatory agents
ES2611403T3 (en)	2011-07-18	2017-05-08	Critical Care Diagnostics, Inc.	Procedures for treating cardiovascular diseases and predicting the effectiveness of exercise therapy
EP2736925A2 (en)	2011-07-27	2014-06-04	Glaxo Group Limited	Anti-vegf single variable domains fused to fc domains
HRP20181457T1 (en)	2011-10-14	2018-11-16	F. Hoffmann - La Roche Ag	ANTI-HTRA1 ANTIBODIES AND USE PROCEDURES
US9090694B2 (en)	2012-04-30	2015-07-28	Janssen Biotech, Inc.	ST2L antibody antagonists
AR091069A1 (en)	2012-05-18	2014-12-30	Amgen Inc	PROTEINS OF UNION TO ANTIGEN DIRECTED AGAINST THE ST2 RECEIVER
MX382403B (en)	2012-08-16	2025-03-13	Critical Care Diagnostics Inc	METHODS FOR PREDICTING THE RISK OF DEVELOPING HYPERTENSION.
US20150250808A1 (en)	2012-10-15	2015-09-10	Vojo P. Deretic	Treatment of autophagy-based disorders and related pharmaceutical compositions, diagnostic and screening assays and kits
US20150259645A1 (en)	2012-11-08	2015-09-17	INSERM (Institut National de la Santé et de la Recherche Médicale	Method for inducing il-2-free proliferation of gamma delta t cells
CA2894219C (en)	2012-12-10	2020-08-11	Vib Vzw	Novel interleukin-33 inhibitors
KR101780575B1 (en)	2013-02-14	2017-09-21	건국대학교 산학협력단	Composition of novel interleukin-33 receptor and binding protein, and use thereof
WO2014128254A1 (en)	2013-02-22	2014-08-28	University Of Eastern Finland (Kuopion Kampus)	Il-33 and treatment of neurodegenerative diseases
JO3532B1 (en)*	2013-03-13	2020-07-05	Regeneron Pharma	Anti-il-33 antibodies and uses thereof
WO2014152195A1 (en)	2013-03-15	2014-09-25	Regeneron Pharmaceuticals, Inc.	Il-33 antagonists and uses thereof
JP6362011B2 (en)	2013-05-01	2018-07-25	学校法人兵庫医科大学	Atopic dermatitis model animal and its use
WO2015042521A1 (en)	2013-09-20	2015-03-26	University Of Virginia Patent Foundation	Compositions and methods for treatment of autoimmune and inflammatory diseases and disorders
ES2733377T3 (en)	2013-10-07	2019-11-28	Univ Pennsylvania	Vaccines with interleukin-33 as an adjuvant
JP6715767B2 (en)	2013-10-23	2020-07-01	ジェネンテック，インコーポレイテッド	Method for diagnosing and treating eosinophilic disease
US20180148489A2 (en)	2013-11-28	2018-05-31	University Of Manitoba	Idr peptide compositions and use thereof for treatment of th2-dysregulated inflammatory conditions
CN112079923A (en)	2013-12-26	2020-12-15	田边三菱制药株式会社	Human anti-IL-33 neutralizing monoclonal antibodies
JP2017503506A (en)	2014-01-10	2017-02-02	アナプティスバイオインコーポレイティッド	Antibody to interleukin-33 (IL-33)
GB201403875D0 (en)	2014-03-05	2014-04-16	Cantargia Ab	Novel antibodies and uses thereof
US20170107300A1 (en)	2014-03-21	2017-04-20	The Brigham And Women's Hospital, Inc.	Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring
WO2015164354A1 (en)	2014-04-21	2015-10-29	The Childen's Hospital Of Philadelphia	Compositions and methods for treating cytokine-related disorders
EP3149049B1 (en)	2014-05-27	2022-10-26	The University Of Queensland	Il-22 for use in treating metabolic disorders
GB201413913D0 (en)	2014-08-06	2014-09-17	Cantargia Ab	Novel antibodies and uses thereof
US20160145344A1 (en)	2014-10-20	2016-05-26	University Of Southern California	Murine and human innate lymphoid cells and lung inflammation
KR20170080604A (en)	2014-11-10	2017-07-10	제넨테크, 인크.	Anti-interleukin-33 antibodies and uses thereof
US20160168640A1 (en)	2014-11-10	2016-06-16	Genentech, Inc.	Therapeutic and diagnostic methods for il-33-mediated disorders
WO2016085832A1 (en)	2014-11-24	2016-06-02	Albert Einstein College Of Medicine, Inc.	Peptides for blocking il1rap protein-protein interaction and uses thereof for treatment of disease
US20170360907A1 (en)	2014-12-04	2017-12-21	The University Of North Carolina At Chapel Hill	Compositions and methods for preventing and treating graft versus host disease
US10539572B2 (en)	2015-01-30	2020-01-21	Salk Institute For Biological Studies	Compositions and methods for treating age-related diabetes and related disorders
EP3265493B1 (en)	2015-03-02	2024-01-10	180 Therapeutics LP	Method of treating a localized fibrotic disorder using an il-33 antagonist
EP3265114A4 (en)	2015-03-03	2019-11-13	Jefferies, Wilfred	MODULATION OF ANTICANCER IMMUNITY USING INNED TYPE 2 LYMPHOID CELLS, INTERLEUKIN 33 AND / OR INTERFERON-INDUCED PROTEIN 44
HK1247287A1 (en)	2015-03-16	2018-09-21	F. Hoffmann-La Roche Ag	Methods of detecting and quantifying il-13 and uses in diagnosing and treating th2-associated diseases
PL3277717T3 (en)	2015-03-31	2021-05-31	Medimmune Limited	A novel il33 form, mutated forms of il33, antibodies, assays and methods of using the same
CN108026172B (en)	2015-06-26	2022-04-29	赛诺菲生物技术公司	Monoclonal anti-IL-1RCP antibody
HK1258529A1 (en)	2015-07-10	2019-11-15	香港科技大学	Methods and compositions for treating neurodegenerative and neuroinflammatory conditions
CL2015002153A1 (en)	2015-07-31	2016-01-29	Pontificia Universidad Católica De Chile	Use of the il-3, il33 and il-12p40 molecular markers to characterize the severity of respiratory infections by respiratory syncytial virus and human metapneumovirus
MA50638A (en)	2015-10-06	2020-08-05	Regeneron Pharma	BIOMARKERS ASSOCIATED WITH INTERLEUKIN-33 (IL-33) MEDIA DISEASES AND THEIR USES
JP2019516362A (en)	2016-04-27	2019-06-20	ファイザー・インク	Anti-IL-33 antibodies, compositions, methods and uses thereof

2015
- 2015-11-10KRKR1020177012891Apatent/KR20170080604A/ennot_activeWithdrawn
- 2015-11-10BRBR112017009728-1Apatent/BR112017009728A2/ennot_activeApplication Discontinuation
- 2015-11-10JPJP2017525046Apatent/JP6929771B2/enactiveActive
- 2015-11-10EPEP20167906.5Apatent/EP3783023A1/ennot_activeWithdrawn
- 2015-11-10WOPCT/US2015/060008patent/WO2016077381A1/enactiveApplication Filing
- 2015-11-10EPEP15797767.9Apatent/EP3218403B1/enactiveActive
- 2015-11-10CACA2960297Apatent/CA2960297A1/ennot_activeAbandoned
- 2015-11-10PEPE2017000823Apatent/PE20170910A1/enunknown
- 2015-11-10AUAU2015346460Apatent/AU2015346460A1/ennot_activeAbandoned
- 2015-11-10USUS14/937,778patent/US10093730B2/enactiveActive
- 2015-11-10SGSG11201703767XApatent/SG11201703767XA/enunknown
- 2015-11-10CNCN201580072740.9Apatent/CN107172879B/enactiveActive
- 2015-11-10EAEA201791029Apatent/EA201791029A1/enunknown
- 2015-11-10MXMX2017006094Apatent/MX2017006094A/enunknown
- 2015-11-10TWTW104137071Apatent/TWI705976B/ennot_activeIP Right Cessation
- 2015-11-10CRCR20170240Apatent/CR20170240A/enunknown
2017
- 2017-03-19ILIL251248Apatent/IL251248A0/enunknown
- 2017-05-09PHPH12017500861Apatent/PH12017500861A1/enunknown
- 2017-06-07COCONC2017/0005650Apatent/CO2017005650A2/enunknown
2018
- 2018-08-31USUS16/119,667patent/US10723795B2/enactiveActive
2020
- 2020-06-16USUS16/903,300patent/US11725050B2/enactiveActive

Also Published As

Publication number	Publication date
PE20170910A1 (en)	2017-07-12
MX2017006094A (en)	2017-07-19
AU2015346460A1 (en)	2017-03-23
TWI705976B (en)	2020-10-01
BR112017009728A2 (en)	2018-02-06
JP6929771B2 (en)	2021-09-01
EP3218403A1 (en)	2017-09-20
JP2018500883A (en)	2018-01-18
WO2016077381A8 (en)	2016-06-30
US10723795B2 (en)	2020-07-28
IL251248A0 (en)	2017-05-29
EA201791029A1 (en)	2017-12-29
KR20170080604A (en)	2017-07-10
US20190092852A1 (en)	2019-03-28
HK1243440A1 (en)	2018-07-13
WO2016077381A1 (en)	2016-05-19
PH12017500861A1 (en)	2017-11-06
CN107172879A (en)	2017-09-15
CR20170240A (en)	2018-04-03
US20210002361A1 (en)	2021-01-07
US10093730B2 (en)	2018-10-09
TW201625683A (en)	2016-07-16
EP3783023A1 (en)	2021-02-24
US11725050B2 (en)	2023-08-15
CN107172879B (en)	2021-11-05
CA2960297A1 (en)	2016-05-19
CO2017005650A2 (en)	2017-08-31
US20160168242A1 (en)	2016-06-16
EP3218403B1 (en)	2020-05-13

Publication	Publication Date	Title
IL283321A (en)	2021-07-29	Anti-muc16 antibodies and uses thereof
IL258284A (en)	2018-05-31	Anti-lag3 antibodies and uses thereof
IL252804A0 (en)	2017-08-31	Anti-c10orf54 antibodies and uses thereof
IL251248A0 (en)	2017-05-29	Anti-interleukin-33 antibodies and uses thereof
IL257263A (en)	2018-03-29	Anti-angptl8 antibodies and uses thereof
ZA201800536B (en)	2019-07-31	Il-8-binding antibodies and uses thereof
ZA201605894B (en)	2019-07-31	Anti-egfrviii antibodies and uses thereof
IL252353A0 (en)	2017-07-31	Antibodies against cd73 and uses thereof
IL251000A0 (en)	2017-04-30	Anti-glucagon antibodies and uses thereof
IL254954A0 (en)	2017-12-31	Anti-pacap antibodies and uses thereof
GB201403875D0 (en)	2014-04-16	Novel antibodies and uses thereof
GB201413913D0 (en)	2014-09-17	Novel antibodies and uses thereof
IL247315A0 (en)	2016-09-29	Anti-acth antibodies and use thereof
ZA201701663B (en)	2023-04-26	Anti-il-25 antibodies and uses thereof
PT3292154T (en)	2022-01-26	Anti-human-her3 antibodies and uses thereof
GB201503387D0 (en)	2015-04-15	Anti-carbapenem antibodies and uses thereof

Movatterモバイル変換

SG11201703767XA - Anti-interleukin-33 antibodies and uses thereof - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (3)

Publications (1)

Family

ID=54608970

Family Applications (1)

Country Status (18)

Families Citing this family (40)

Family Cites Families (192)

Also Published As

Similar Documents